-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16

Benzinga·05/14/2025 17:10:30
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $20 to $16.